{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"142-437-149-990-825","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"142-437-149-990-825"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11797,"type":"PATENT","title":"Queen's University at Kingston Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5666,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8427,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: queen* AND univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1261
Search Applicants and Owners separately: queen* AND univ*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1261
wherein each of E, F, and G is an organic radical which may contain inorganic counterion,\n
wherein F and G are not substituted or unsubstituted pyridyl, and\n
wherein, when E is a C1 alkane, F and G are not both C1 to C3 alkyl radicals bearing one or more nitrate groups or an O linkage."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein administering the therapeutic compound to said subject modulates levels of cyclic nucleotide cGMP and/or cAMP."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein administering the therapeutic compound to said subject modulates cellular free radical damage."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["A method for inhibiting neurodegeneration or effecting neuroprotection in a subject in need thereof, said method comprising administering to said subject an effective amount of a therapeutic compound such that said neurodegeneration is inhibited or said neuroprotection is effected, wherein said therapeutic compound has the formula: \n\nin which:\n
each of m, n, p is an integer of from 0 to 10;\n
R3,17 are each independently hydrogen, a nitrate group, or A;\n
R1,4 are each independently hydrogen or A;\n
A is selected from: a substituted or unsubstituted aliphatic group having from 1 to 24 carbon atoms in the chain, which optionally contains O, S, and/or N and/or unsaturations in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted cyclic aliphatic moiety having from 3 to 7 carbon atoms in the aliphatic ring, which optionally contains O, S, NR6 or an unsaturation in the ring, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted aliphatic moiety comprising a linkage of from 0 to 5 carbon atoms between R1 and R3 and/or between R17 and R4, which optionally contains O, S, NR6, or an unsaturation in the linkage, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aliphatic group having from 1 to 24 carbon atoms in the chain, containing ii ages selected from C═O, C═S, and C═NOH, which optionally contains O, S, NR6, or an unsaturation in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aryl group; a substituted or unsubstituted heterocyclic group; an amino group selected from alkylamino, dialkylamino, cyclic amino, cyclic diamino, cyclic triamino, arylamino, diarylamino, and alkyarylamino; a hydroxy group; an alkoxy group; and a substituted or unsubstituted aryloxy group;\n
each of R2, R5, R18, and R19 is, independently, hydrogen, A, or X-Y;\n
X is F, Br, Cl, NO2, CH2, CF2, O, NH, NMe, CN, NHOH, N2H3, N2H2R13, N2HR13R14, N3, S, SCN, SCN2H2(R15)2, SCN2H3(R15), SC(O)N(R15)2, SC(O)NHR15, SO3M, SH, SR7, SO2M, S(O)R8, S(O)2R9, S(O)OR8, S(O)2OR9, PO2HM, PO3HM, PO3M2, P(O)(OR15)(OR16), P(O)(OR16)(OM), P(O)(R15)(OR8), P(O)(OM)R15, CO2M, CO2H, CO2R11, C(O), C(O)R12, C(O)(OR13), PO2H, PO2M, P(O)(OR14), P(O)(R13), SO, SO2, C(O)(SR13), SR7, SSR7 or SSR5;\n
Y is F, Br, Cl, CH3, CF2H, CF3, OH, NH2, NHR6, NR6R7, CN, NHOH, N2H3, N2H2R13, N2HR13R14, N3, S, SCN, SCN2H2(R15)2, SCN2H3(R15), SC(O)N(R15)2, SC(O)NHR15, SO3M, SH, SR7, SO2M, S(O)R8, S(O)2R9, S(O)OR8, S(O)2OR9, PO2HM, PO3M2, P(O)(OR15)(OR16), P(O)(OR16)(OM), P(O)(R15)(OR8), P(O)(OM)R15, CO2M, CO2H, CO2R11, C(O)R12, C(O)(OR13), C(O)(SR13), SR5, SSR7 or SSR5, or does not exist;\n
each of R6, R7, R8, R9, R11, R12, R13, R14, R15, and R16 is, independently, an alkyl or acyl group containing 1-24 carbon atoms, which may contain 1-4 ONO2 substituents; a C1-C6 connection to R1-R4 in a cyclic derivative; a hydrogen, a nitrate group or A; and\n
M is H, Na+, K+, NH4+, or N+HkR11(4-k) where k is 0-3, or other pharmaceutically acceptable counterion;\n
wherein A is not substituted or unsubstituted pyridyl, and,\n
when m=n=p=1, that each of R1, R2, R18, and R19 is, independent y, selected from the group consisting of H, O linkage, and C1-C2 alkyl, wherein said C1-C2 alkyl is optionally substituted with nitrate, that each of R3 and R17 is, independently, selected from the group consisting of H, nitrate, O linkage, and C1-C2 alkyl, wherein said C1-C2 alkyl is optionally substituted with nitrate, and that R4 is not H or C1-C3 alkyl."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein R19 is X—Y."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein:\n
R1 and R3 are the same or different and selected from H, a C1-C4 , alkyl chain, or a linkage, which may include one O, linking R1 and R3 to form pentosyl, hexosyl, cyclopentyl, or cyclohexyl rings, which rings optionally bear hydroxyl substituents;\n
R2 and R4, are the same or different and selected from H, a nitrate group, a alkyl chain, optionally bearing 1-3 nitrate groups, and an acyl group (—C(O)R5;\n
R7 and R11 are the same or different and selected from C1-C8 alkyl and C1-C8 acyl;\n
each of R5, R6, R8, R9, R11, R12, R13, 14, R15, and R16 is, independently an alkyl or acyl group containing 1-24 carbon atoms, which may contain 1-4 ONO2 substituents; or a C1 or C2 connection to R1-R3 a cyclic derivative; and\n
M is H, Na+, K+, NH4+, or N+HkR11(4-k), where k is 0-3."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein m=1, n=0, and p=1."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein:\n
X is CH2, O, NH, NMe, CN, NHOH, N2H3, N2H2R13, N2HR13R14, N3, S, SCN, SCN2H2(R15)2, SCN2H3(R15), SC(O)N(R15)2, SC(O)NHR15, SO3M, SH, SR7, SO2M, S(O)R8, S(O)2R9, S(O)OR8, S(O)2OR9, PO3HM, PO3M2, P(O)(OR15)(OR16), P(O)(OR16)(OM), P(O)(R15)(OR8), P(O)(OM)R15, CO2M, CO2H, CO2R11, (O), C(O), C(O)R12, C(O)(OR13), PO2M, P(O)(OR14), P(O)(R13), SO, SO2, C(O)(SR13), SSR5; and\n
Y is CN, N2H2R13, N2HR13R14, N3, SCN, SCN2H2(R15)2, SC(O)NHR15, SO3M, SR4, SO2M, PO3HM, PO3M2, P(O)(OR15)(OR16), P(O)(OR16)(OM), P(O)(R15)(OR8), P(O)(OM)R15, CO2M, CO2H, CO2R11, C(O)R12, C(O)(SR13), SR5, SSR5, or does not exist."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein:\n
each of R5, R6, R8, R9, R12, R13, R14, R15, and R16 is, independently, a alkyl group containing 1-12 carbon atoms or a C1 or C2 connection to or R3 in a cyclic derivative;\n
X is CH2, O, NH, NMe, S, SO3M, SH, SR7, SO2M, S(O)R8, S(O)2R9, S(O)OR8, S(O)2OR9, PO3M2, P(O)(OR15)(OR16), P(O)(OR16)(OM), P(O)(R15)(OR8), O3HM or P(O)(OM)R15; and\n
Y is SO2M, SO3M, PO3HM, PO3M2, P(O)(OR15)(OR16), P(O)(OR16) OM), SR5, SSR7 or SSR5, or does not exist."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said therapeutic compound is administered orally, intravenously, buccally, transdermally or subcutaneously."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising a ministering said therapeutic compound in a pharmaceutically acceptable vehicle."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein administering said therapeutic compound to said subject modulates an activity of the glutamate neuroreceptor."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein administering said therapeutic compound to said subject modulates an activity of a non-glutamate neuroreceptor."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein administering said therapeutic compound to said subject modulates cerebral guanylyl cyclase activity."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein administering said therapeutic compound to the subject modulates apoptosis."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said therapeutic compound is administered orally, intravenously, buccally, transdermally or subcutaneously."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising a ministering said therapeutic compound in a pharmaceutically acceptable vehicle."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein p=1 and each of R6, R7, R8, R9, R11, R12, R13, R14, R15, and R16 is, independently, an alkyl or acyl group containing 1-24 carbon atoms, which may contain 1-4 ONO2 substituents, or is a C1-C6 connection to R1-R4 a cyclic derivative."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein X is SSR5 or SSR7, and Y does not exist."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 18, wherein R18 A, m=1, and n=0-1."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 18, wherein each of m, n, and p is an integer from 0-2 and R5 is A."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 21, wherein A is selected from: a substituted or unsubstituted aliphatic group having from 1 to 24 carbon atoms in the chain, which optionally contains O, S, NR6, or an unsaturation in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted cyclic aliphatic moiety having from 3 to 7 carbon atoms in the aliphatic ring, which optionally contains O, S, NR6, or an unsaturation in the ring, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted aliphatic moiety comprising a linkage of from 0 to 5 carbon atoms between R1 and R3 and/or between R17 and R4, which optionally contains O, S, NR6, or an unsaturation in the linkage, and optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aliphatic group having from 1 to 24 carbon atoms in the chain, containing linkages selected from C═O, C═S, and C═NOH, which optionally contains O, S, NR6, or an unsaturation in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aryl group; a substituted or unsubstituted heterocyclic group; an amino group selected from alkylamino, dialkylamino, cyclic amino, cyclic diamino, cyclic triamino, arylamino, diarylamino, and alkyarylamino; a hydroxy group; an alkoxy group; and a substituted or unsubstituted aryloxy group."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein m=n=p=1; R1, R2, R3, R4, and R18 are H; R17 is nitrate; and R19 is SSR5, where R5 is A, and where A is a substituted or unsubstituted heterocyclic group."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein m=n=p=1; R1, R2, R3, R4, and R18 are H; R17 is nitrate; and R19 is SSR5, where R5 is A, and where A is a substituted or unsubstituted aryl group."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein m=n=p=1; R1, R2, R3, R4, and R18 are H; R17 is nitrate; and R19 is SSR5, where R5 is A, and where A is a substituted or an unsubstituted cyclic aliphatic moiety having from 3 to 7 carbon atoms in the aliphatic ring, which optionally contains O, S, NR6, or an unsaturation in the ring, optionally bearing from 1 to 4 hydroxy, or nitrate, or amino or aryl, or heterocyclic groups; a substituted or unsubstituted aliphatic group having from 1 to 24 carbon atoms in the chain, containing linkages selected from CO, C═S, and C═NOH, which optionally contains O, S, NR6, or an unsaturation in the chain, optionally bearing from 1 to 4 hydroxy, or nitrate, or amino or aryl, or heterocyclic groups."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein m=n=p=1; R1, R2, R3, R4, and R18 are H; R17 nitrate; and R19 is SSR5, where R5 is A, and where A is a substituted or unsubstituted aliphatic group having from 1 to 24 carbon atoms in the chain, which optionally contains O, S, NHR6, or an unsaturation in the chain, optionally bearing from 1 to 4 hydroxy, or nitrate, or amino or aryl, or heterocyclic groups."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["A method for inhibiting neurodegeneration or effecting neuroprotection in a subject in need thereof, said method comprising administering to said subject an effective amount of a therapeutic compound such that said neurodegeneration is inhibited or said neuroprotection is effected, wherein said therapeutic compound has a formula selected from the group consisting of:"],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["A method for inhibiting neurodegeneration or effecting neuroprotection in a subject in need thereof, said method comprising administering to said subject an effective amount of a therapeutic compound such that said neurodegeneration is inhibited or said neuroprotection is effected, wherein said therapeutic compound has the formula:"],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, wherein A is a substituted or unsubstituted aliphatic group having from 1 to 24 carbon atoms in the chain bearing aryl or heterocyclic groups."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein administering said therapeutic compound to the subject modulates cellular free radical damage."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein said therapeutic compound is administered orally, intravenously, buccally, transdermally or subcutaneously."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, further comprising administering said therapeutic compound in a pharmaceutically acceptable vehicle."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein administering said therapeutic compound to said subject modulates an activity of the glutamate neuroreceptor."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein administering said therapeutic compound to said subject modulates an activity of a non-glutamate neuroreceptor."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein administering said therapeutic compound to said subject modulates cerebral guanylyl cyclase activity."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein administering said therapeutic compound to said subject modulates apoptosis."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein administering said therapeutic compound to said subject modulates apoptosis."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein administering said therapeutic compound to said subject modulates cellular free radical damage."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein administering said therapeutic compound to said subject modulates cerebral guanylyl cyclase activity."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein administering said therapeutic compound to said subject modulates levels of the cyclic nucleotides cGMP and/or cAMP."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said neurodegeneration is due to myocardial infarction or a surgical procedure."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said neurodegeneration is due to myocardial infarction or a surgical procedure."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, further comprising a ministering said compound in a pharmaceutically acceptable vehicle."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 28, further comprising a ministering said therapeutic compound in a pharmaceutically acceptable vehicle."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said neurodegeneration or said neuroprotection is associated with a condition selected from the group consisting of stroke, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced dementia, epilepsy, alcoholism, alcohol withdrawal, drug-induced seizure, viral/bacterial/fever-induced seizure, trauma to the head, hypoglycemia, hypoxia, myocardial infarction, cerebral vascular occlusion, cerebral vascular hemorrhage, hemorrhage, an environmental excitotoxin, dementia, trauma, drug-induced brain damage, and aging."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said neurodegeneration or said neuroprotection is associated with dementia."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said neurodegeneration or said neuroprotection is associated with Alzheimer's disease."],"number":47,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 45, wherein said therapeutic compound is administered by a route selected from the group consisting of sublingual, oral, buccal, transdermal, nasal, subcutaneous, intravenous, intramuscular and intraperitoneal injection."],"number":48,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 45, wherein said therapeutic compound is administered with a pharmaceutically acceptable vehicle."],"number":49,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said therapeutic compound inhibits dementia."],"number":50,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said therapeutic compound inhibits Alzheimer's disease."],"number":51,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein said therapeutic compound inhibits dementia."],"number":52,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 27, wherein said therapeutic compound inhibits Alzheimer's disease."],"number":53,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 28, wherein said therapeutic compound inhibits dementia."],"number":54,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 28, wherein said therapeutic compound inhibits Alzheimer's disease."],"number":55,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}